Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

LNK (SH2B3): paradoxical effects in ovarian cancer.

Ding LW, Sun QY, Lin DC, Chien W, Hattori N, Dong XM, Gery S, Garg M, Doan NB, Said JW, Xiao JF, Yang H, Liu LZ, Meng X, Huang RY, Tang K, Koeffler HP.

Oncogene. 2015 Mar 12;34(11):1463-74. doi: 10.1038/onc.2014.34. Epub 2014 Apr 7.

2.

Expression of the adaptor protein Lnk in leukemia cells.

Gery S, Gueller S, Nowak V, Sohn J, Hofmann WK, Koeffler HP.

Exp Hematol. 2009 May;37(5):585-592.e2. doi: 10.1016/j.exphem.2009.01.009.

PMID:
19375649
3.

Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells.

Simon C, Dondi E, Chaix A, de Sepulveda P, Kubiseski TJ, Varin-Blank N, Velazquez L.

Blood. 2008 Nov 15;112(10):4039-47. doi: 10.1182/blood-2008-05-154849. Epub 2008 Aug 27.

4.

Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis.

Tong W, Lodish HF.

J Exp Med. 2004 Sep 6;200(5):569-80. Epub 2004 Aug 30.

5.

Growth and maturation of megakaryocytes is regulated by Lnk/Sh2b3 adaptor protein through crosstalk between cytokine- and integrin-mediated signals.

Takizawa H, Eto K, Yoshikawa A, Nakauchi H, Takatsu K, Takaki S.

Exp Hematol. 2008 Jul;36(7):897-906. doi: 10.1016/j.exphem.2008.02.004. Epub 2008 May 5.

PMID:
18456388
6.

Differential functions of growth factor receptor-bound protein 7 (GRB7) and its variant GRB7v in ovarian carcinogenesis.

Wang Y, Chan DW, Liu VW, Chiu P, Ngan HY.

Clin Cancer Res. 2010 May 1;16(9):2529-39. doi: 10.1158/1078-0432.CCR-10-0018. Epub 2010 Apr 13. Erratum in: Clin Cancer Res. 2016 Mar 1;22(5):1296.

7.

LNK (SH2B3) is a key regulator of integrin signaling in endothelial cells and targets α-parvin to control cell adhesion and migration.

Devallière J, Chatelais M, Fitau J, Gérard N, Hulin P, Velazquez L, Turner CE, Charreau B.

FASEB J. 2012 Jun;26(6):2592-606. doi: 10.1096/fj.11-193383. Epub 2012 Mar 21.

8.

Functional roles of Src and Fgr in ovarian carcinoma.

Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MM, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala LS, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, Sood AK.

Clin Cancer Res. 2011 Apr 1;17(7):1713-21. doi: 10.1158/1078-0432.CCR-10-2081. Epub 2011 Feb 7.

9.

14-3-3 regulates the LNK/JAK2 pathway in mouse hematopoietic stem and progenitor cells.

Jiang J, Balcerek J, Rozenova K, Cheng Y, Bersenev A, Wu C, Song Y, Tong W.

J Clin Invest. 2012 Jun;122(6):2079-91. doi: 10.1172/JCI59719. Epub 2012 May 1.

10.

Upregulation of DLX5 promotes ovarian cancer cell proliferation by enhancing IRS-2-AKT signaling.

Tan Y, Cheung M, Pei J, Menges CW, Godwin AK, Testa JR.

Cancer Res. 2010 Nov 15;70(22):9197-206. doi: 10.1158/0008-5472.CAN-10-1568. Epub 2010 Nov 2.

11.

Octa-arginine mediated delivery of wild-type Lnk protein inhibits TPO-induced M-MOK megakaryoblastic leukemic cell growth by promoting apoptosis.

Looi CY, Imanishi M, Takaki S, Sato M, Chiba N, Sasahara Y, Futaki S, Tsuchiya S, Kumaki S.

PLoS One. 2011;6(8):e23640. doi: 10.1371/journal.pone.0023640. Epub 2011 Aug 10.

12.

Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways.

Tong W, Zhang J, Lodish HF.

Blood. 2005 Jun 15;105(12):4604-12. Epub 2005 Feb 10.

13.

PRL-3 suppresses c-Fos and integrin α2 expression in ovarian cancer cells.

Liu H, Al-aidaroos AQ, Wang H, Guo K, Li J, Zhang HF, Zeng Q.

BMC Cancer. 2013 Feb 18;13:80. doi: 10.1186/1471-2407-13-80.

14.

Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.

Kawaguchi H, Terai Y, Tanabe A, Sasaki H, Takai M, Fujiwara S, Ashihara K, Tanaka Y, Tanaka T, Tsunetoh S, Kanemura M, Ohmichi M.

J Ovarian Res. 2014 Apr 9;7:38. doi: 10.1186/1757-2215-7-38.

15.

Role of PELP1/MNAR signaling in ovarian tumorigenesis.

Dimple C, Nair SS, Rajhans R, Pitcheswara PR, Liu J, Balasenthil S, Le XF, Burow ME, Auersperg N, Tekmal RR, Broaddus RR, Vadlamudi RK.

Cancer Res. 2008 Jun 15;68(12):4902-9. doi: 10.1158/0008-5472.CAN-07-5698.

16.

Plexin-B1 silencing inhibits ovarian cancer cell migration and invasion.

Ye S, Hao X, Zhou T, Wu M, Wei J, Wang Y, Zhou L, Jiang X, Ji L, Chen Y, You L, Zhang Y, Xu G, Zhou J, Ma D, Wang S.

BMC Cancer. 2010 Nov 8;10:611. doi: 10.1186/1471-2407-10-611.

17.

Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.

Hu C, Huang L, Gest C, Xi X, Janin A, Soria C, Li H, Lu H.

J Hematol Oncol. 2012 Jul 11;5:16. doi: 10.1186/1756-8722-5-16.

18.

WAVE1 gene silencing via RNA interference reduces ovarian cancer cell invasion, migration and proliferation.

Zhang J, Zhou S, Tang L, Shen L, Xiao L, Duan Z, Jia L, Cao Y, Mu X.

Gynecol Oncol. 2013 Aug;130(2):354-61. doi: 10.1016/j.ygyno.2013.05.005. Epub 2013 May 13.

PMID:
23680521
19.

Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells.

Gery S, Xie D, Yin D, Gabra H, Miller C, Wang H, Scott D, Yi WS, Popoviciu ML, Said JW, Koeffler HP.

Clin Cancer Res. 2005 Oct 15;11(20):7243-54.

20.

Death domain-associated protein DAXX promotes ovarian cancer development and chemoresistance.

Pan WW, Zhou JJ, Liu XM, Xu Y, Guo LJ, Yu C, Shi QH, Fan HY.

J Biol Chem. 2013 May 10;288(19):13620-30. doi: 10.1074/jbc.M112.446369. Epub 2013 Mar 28.

Items per page

Supplemental Content

Write to the Help Desk